Dr. Michael Lincoff is a globally recognized leader in cardiovascular clinical research, with over three decades of experience designing and leading landmark trials in interventional cardiology, acute coronary syndromes, and cardiometabolic disease. He has served as Principal or Co-Principal Investigator on numerous pivotal studies, including SELECT, CLEAR Outcomes, TRAVERSE, HORIZON, ACCELERATE, STRENGTH, and AleCardio, among others.
Dr. Lincoff has authored over 400 peer-reviewed publications and has played a central role in shaping FDA guidance and clinical trial endpoint definitions through his work with the Cardiovascular and Renal Drugs Advisory Committee and the Clinical Trials Transformation Initiative.
He is currently a Professor Emeritus of Medicine at the Cleveland Clinic Lerner College of Medicine and continues to serve as a Contract Staff Interventional Cardiologist at the Cleveland Clinic.
KEY HIGHLIGHTS
- Antithrombotic therapies (e.g., bivalirudin, glycoprotein IIb/IIIa inhibitors)
- Lipid-lowering agents (e.g., bempedoic acid, CETP inhibitors)
- Cardiometabolic interventions (e.g., semaglutide, testosterone therapy)
- Device-based and pharmacologic strategies for PCI and ACS
